5PSQ-004 Analysis of symptomatic rescue therapy in patients with galcanezumab for migraine prophylaxis
Year: 2025
Type: conference-paper
Study design: Observational Study
Abstract: Background and Importance Pharmacological treatment of migraine is divided into two types: symptomatic rescue and prophylactic treatment. Symptomatic treatment includes paracetamol and nonsteroidal anti-inflammatory drugs, as conventional analgesics, and triptans. Profilactic treatment includes calcitonin gene-related peptide as galanezumab, erenumab, fremanezumab and eptinezumab Aim and Objectives To analyse the symptomatic treatment in patients diagnosed with chronic migraine (CM) and episodic migraine (EM) under prophylactic treatment with galcanezumab. Material and Methods Retrospective descriptive observational study of 31 months duration (January 2021 to July 2023). All patients treated with galcanezumab were included. Patients with other diagnoses were excluded. Sex, age at drug initiation, diagnosis, and symptomatic rescue therapy used since the start of galcanezumab treatment were recorded. Materials: outpatient dispensing module, electronic history program. Results Thirty-six patients were included, 88.9% women, mean age at the beginning with galcanezumab therapy was 45.4 years (26–81). 66.7% of patients had CM and 33.3% had EM. 94.4% of patients needed rescue treatment during migraine attacks. During galcanezumab treatment, conventional analgesics were used by 75.0% of CM patients and by 66.7% of EM patients. Conventional analgesics used were: 33.3% of CM patients and 25.0% of EM patients took more than one analgesic. Triptans use was 75.0% in CM patients and 83.3% in EM patients. Triptans consumed were: More than one triptan was used by 4.2% of CM patients and 16.7% of EM patients. Patients using both types of drugs concomitantly were 58.3% of CM patients and 50.0% of EM patients. Conclusion and Relevance Nearly all patients (94.4%) attended symptomatic treatment during galcanezumab treatment. Triptans were the most commonly used drugs in patients with CM and EM. The most commonly used triptan in CM was rizatriptan and in EM it was sumatriptan. Dexketoprofen was the conventional analgesic most used by both populations. More than a half of the patients took both types of drugs during migraine attacks. References and/or Acknowledgements Conflict of Interest No conflict of interest
Authors: I Ureña, I Fernández Cebrecos, GT Bajenaru, M Martín Rodriguez, C González Trigueros, G Raguan Yáñez, AG Lopez Del Río, ME Beltrán Bellvis, A Martín Velasco, C San Andrés Corral, C Escrigas Fernández
Institution: Hospital Universitario Príncipe de Asturias
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4408377154